Ceftazidime Meaning
Ceftazidime is a third-generation cephalosporin antibiotic used to treat serious bacterial infections caused by gram-negative organisms and some gram-positive bacteria. It is administered intravenously or intramuscularly and is particularly valued for its effectiveness against Pseudomonas aeruginosa, a notoriously difficult-to-treat pathogenic bacterium.
What Does Ceftazidime Mean?
Ceftazidime is a beta-lactam antibiotic belonging to the third-generation cephalosporin class of antimicrobial drugs. It was first synthesized and approved for clinical use in the early 1980s, representing a significant advancement in treating hospital-acquired and serious community infections resistant to earlier antibiotic generations.
Chemical Structure and Mechanism
The drug functions by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins and disrupting peptidoglycan cross-linking. This bactericidal action makes it effective against a broad spectrum of gram-negative aerobic bacteria, including the notoriously resistant Pseudomonas aeruginosa. Its structural design—featuring a specific side chain configuration—provides superior penetration of bacterial cell membranes compared to first and second-generation cephalosporins.
Clinical Applications
Ceftazidime is commonly prescribed for nosocomial (hospital-acquired) infections, cystic fibrosis-related lung infections, febrile neutropenia in cancer patients, and meningitis caused by susceptible organisms. Healthcare providers often select ceftazidime for empirical therapy in critically ill patients when gram-negative coverage is essential. The drug demonstrates excellent tissue penetration, including into cerebrospinal fluid, making it suitable for serious central nervous system infections.
Administration and Dosing
Ceftazidime requires parenteral administration—either intravenous or intramuscular injection—because oral bioavailability is negligible. Typical dosing ranges from 1-2 grams administered every 8-12 hours, with adjustments for renal impairment. The drug has a relatively short half-life of approximately 1.5-2 hours, necessitating regular dosing intervals.
Resistance and Evolution
While ceftazidime remains highly effective, resistance mechanisms have emerged over decades of use, particularly extended-spectrum beta-lactamase (ESBL) production and AmpC beta-lactamase expression in certain bacterial species. In response to increasing resistance, ceftazidime-avibactam—a combination formulation pairing ceftazidime with a beta-lactamase inhibitor—was developed to restore efficacy against resistant organisms.
Safety Profile
Ceftazidime generally exhibits favorable tolerability with adverse effects similar to other cephalosporins. Cross-reactivity with penicillin allergies occurs in approximately 1-3% of patients. Nephrotoxicity and neurotoxicity are rare but documented, particularly with high doses or renal impairment.
Key Information
| Characteristic | Details |
|---|---|
| Drug Class | Third-generation cephalosporin (beta-lactam) |
| Spectrum | Gram-negative aerobes, Pseudomonas aeruginosa, some gram-positive bacteria |
| Administration Route | Intravenous or intramuscular injection |
| Half-life | 1.5-2 hours |
| Typical Dose | 1-2 grams every 8-12 hours |
| FDA Approval | 1985 (original formulation) |
| Renal Adjustment | Required for CrCl <50 mL/min |
| Common Resistance Mechanisms | ESBL production, AmpC beta-lactamase |
Etymology & Origin
Modern pharmaceutical nomenclature (1981); derived from cephalosporin class structure with systematic chemical naming conventions